This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury
Anthony J. Bella1, 2, Guiting
Lin3, Ilias Cagiannos2, Tom F. Lue3, 4
1Department of Surgery, Division of Urology,
2Department of Neuroscience, Ottawa Health Research Institute, University
of Ottawa, Ottawa K1Y4E9, Canada
3Knuppe Molecular Urology Laboratory and
4Department of Urology, University of California, San Francisco, CA 94143, USA
Abstract
Advances in the neurobiology of growth factors, neural development, and prevention of cell death have resulted in
a heightened clinical interest for the development of protective and regenerative neuromodulatory strategies for the
cavernous nerves (CNs), as therapies for prostate cancer and other pelvic malignancies often result in neuronal
damage and debilitating loss of sexual function. Nitric oxide released from the axonal end plates of these nerves within
the corpora cavernosa causes relaxation of smooth muscle, initiating the haemodynamic changes of penile erection as
well as contributing to maintained tumescence; the loss of CN function is primarily responsible for the development of
erectile dysfunction (ED) after pelvic surgery and serves as the primary target for potential neuroprotective or
regenerative strategies. Evidence from pre-clinical studies for select neuromodulatory approaches is reviewed, including
neurotrophins, glial cell line-derived neurotrophic factors (GDNF), bone morphogenic proteins, immunophilin ligands,
erythropoetin (EPO), and stem cells. (Asian J Androl 2008 Jan; 10: 54_59)
Keywords: erectile dysfunction; prostate cancer; radical prostatectomy; postoperative complications; neuroprotection; nerve regeneration;
neurotrophins; brain-derived nerve growth factor; immunophilin ligands; stem cells
Correspondence to: Dr Anthony J. Bella, The Ottawa Hospital, Civic Campus, B3_Division of Urology, 1053 Carling Avenue, Ottawa
K1Y 4E9, Canada.
Tel: +1-613-761-4500 Fax: +1-613-761-5305
E-mail: anthonybella@gmail.com
DOI: 10.1111/j.1745-7262.2008.00368.x
1 Introduction and background
The clinical potential of neuromodulatory therapy is based upon the recognition that although the peripheral
nervous system demonstrates an intrinsic ability to regenerate after injury, this endogenous response is somewhat
limited and does not usually allow for a full recovery of function [1]. Erectile dysfunction (ED) remains a common
cause of significant post-operative morbidity for men undergoing radical therapies for prostate cancers or other pelvic
malignancies, as the cavernous nerves (CNs) are inadvertently axotomized, lacerated, or stretched at time of surgery
[2, 3]. Contemporary data indicates that the probability of ED following radical prostatectomy for clinically localized
cancer of the prostate is 20_90% at 24 months [2]. Although refinements in anatomic surgical technique, as
evidenced by an improved understanding of penile autonomic innervation and the implementation of such innovative
technological advances as laparoscopic and robot-assisted surgery, has led to significant improvements in
post-operative erectile function, most men demonstrate compromised erectile function (delayed, compromised or lack of
post-surgical potency) as varying degrees of CN damage occur even with successful bilateral nerve-sparing
procedures [4]. With CN compromise (ranging from neuropraxia to lethal axonal damage), well-defined pathobiological
changes are observed in the penis, including apoptosis of smooth muscle and endothelium, reduction of nitric oxide
synthase (NOS) nerve density, up-regulation of fibroproliferative cytokines such as transforming growth factor beta
(TGF-β), and smooth muscle fibrosis or loss [1, 2]. Additionally, the chronic absence of erection secondary to CN
neuropraxia results in failure to achieve cavernosal cycling between flaccid and erect state, with the potential for
further structural damage to the cavernosal smooth muscle [5].
Preservation of the CNs during radical prostatectomy
is a key variable for maintaining post-operative erectile
function because downstream events, including smooth
muscle apoptosis, cavernosal fibrosis, and venous leak
are thought to result from CN injury; a clear clinical need
for the development of therapeutic neuromodulatory
interventions has been defined, as both sympathetic and
parasympathetic pelvic innervation is at high risk of
injury during surgery or radiation therapy for prostate,
bladder, and colorectal malignancies [2_4]. For example,
achieving cancer-control, continence and potency is
limited to approximately 60% of men at 24 months after having
open radical retropubic prostatectomy for clinically
localized disease [6].
Penile erection, controlled by adrenergic, cholinergic,
and nonadrenergic noncholinergic (NANC) neuroeffectors of the CNs, is often compromised by these
treatments and patient and partner quality-of-life is
markedly reduced [7]. Accumulating evidence suggests that
a return to potency following injury to the CNs is
partially dependent upon axonal regeneration in the
remaining neural tissues and several treatment strategies
offering the potential to facilitate recovery are currently under
investigation in animal models, including neurotrophins,
growth factors, immunophilin ligands, and stem cells
[8_10]. Collateral sprouting of axons occurs acutely
following injury to adult peripheral neurons and growth
cones target local environments supportive of
regeneration [11]. However, the specific molecular mechanisms
responsible for survival and the preservation of function
for adult parasympathetic ganglion neurons, including the
CNs, following injury remain incompletely understood.
Although phosphodiesterase type-5 (PDE-5) inhibitors
have revolutionized the treatment of ED, compromised
erectile function following radical prostatectomy remains
a therapeutic challenge [12]. The restoration of erectile
function is optimized only if it becomes possible to
stimulate nerve growth to re-establish penile innervation and
surviving or recoverable axons are protected in the
post-traumatic period from further deterioration or death. As
the molecular understanding of the neural response to
injury and mechanisms of recovery expands, treatment
strategies using signalling pathway modulators, neurotrophic
factors, stem cells, or novel combinations of these
molecules/agents, offer the potential to modulate the CN
microenvironment and promote repair and survival [13].
2 Neurotrophins
Neurotrophin polypeptides regulate neuronal survival
though a series of signaling pathways, including those
mediated by G-proteins, ras, cdc-42/ras/rho, and PI-3
kinase cascades [14]. The ability of neurotrophic
factors to enhance functional recovery after cavernosal nerve
injury has been shown via direct injection of neurotrophic
factors and gene therapy with adeno-associated
virus-mediated neurotrophic factor production [15].
Brain-derived neurotrophic factor (BDNF), a member of the
mammalian family of neurotrophins which also includes
nerve growth factor (NGF), and neurotrophins 3, 4, and
5, has been the focus of intense investigation because of
its central role in neuronal development, maturation,
survival after injury, and demonstrable retrograde axonal
transport to the cell body [16]. Retrograde transport of
neurotrophic factors occurs as molecules are taken up
by the neural synapses of the corpus cavernosum and
travel to the major pelvic ganglion to exert their
neuroprotective/regenerative effects [17].
2.1 BDNF
A growing body of literature suggests BDNF may represent a promising neuromodulatory therapeutic agent,
enhancing neuronal survival, differentiation, and
regeneration alone or synergistically with other molecules.
Functional studies have determined that
BDNF-secreting fibroblasts promote recovery of bladder and hindlimb
function following spinal cord contusion, while Lue's
group has demonstrated BDNF-enhanced recovery of erectile function, BDNF/vascular endothelial growth
factor synergies, and regeneration of neuronal NOS
(nNOS)-containing nerve fibres [18, 19].
BDNF has been shown to exert its effects on several classes of neurons, acting
in an autocrine or paracrine fashion early after nerve
injury when a rapid influx of growth factors occurs
distally to the site of trauma. Recent identification of the
JAK/STAT signaling pathway as the primary mechanism
responsible for in vitro BDNF-mediated cavernous
neurite outgrowth (Figures 1 and 2) and subsequent
observations that CN axotomy up-regulates in
vivo expression of penile BDNF and leads to endogenous activation
of the JAK/STAT pathway illustrates both the gaps in
contemporary knowledge and the potential for
elucidating these important mechanisms [8, 14, 16]. Subsequently,
the membrane receptors JAK1 and JAK2, and downstream molecules including STAT1, 2, 3 and 5 have
become key components for further study of the CN
response to injury.
3 Glial cell-line derived neurotrophic factor (GDNF)
GDNFs include the molecules GDNF, neurturin (NTN), persephin, and artemin. This class of compounds
represent a novel group of neuroprotective and
neuroregenerative agents [20, 21]. Initial in
vitro studies suggested NTN acts as a target-derived survival and/or
neuritogenic factor for penile erection-inducing
postganglionic neurons via a neurotrophic signaling mechanism
distinct from other parasympathetic neurons and
mediated by the GDNF family receptors α1, α2 (predominant)
and α4 [22]. Bella et al. [20] first
demonstrated neurturin's ability to confer an in
vivo advantage for the functional recovery of erectile function following CN injury, as
neurturin applied directly to the area of CN injury
facilitated the preservation of erectile function as compared
to untreated control rats and those treated with extended
release neurotrophin-4 [20]. Neurturin facilitated the
preservation of erectile function, with a mean ICP increase of
55% (net increase of 62.0 ± 9.2 cm
H2O (P < 0.05 vs. control), and the extended
5-week course of treatment was well tolerated.
Subsequently, Kato et al. [21] reported the use of a herpes simplex virus vector
expressing GDNF as the delivery mechanism to the site of injury,
with significant functional recovery observed as well.
As penis-projecting pelvic neurons express nNOS and
GFRα2, accumulating tissue culture, cell-line, in
vivo signaling, and functional evidence suggests that neurturin
and GDNF play a role in regeneration, as well as
maintenance, of adult parasympathetic neurons.
4 GDF-5
Growth differentiation factor-5 (GDF-5), a member
of the TGF-B superfamily, is a more recently isolated
neurotrophic factor and is classified as a bone
morphogenic protein [23]. GDF-5's molecular structure was
first characterized in 2005 and effector pathways include
intermediary mitogen-activated protein kinase
(MAPK)-dependent pathways [24] that effector pathways include
intermediary serine/threonine kinase receptors, namely,
bone morphogenic protein (BMP) receptor Ib (BMPRIb),
BMPR2 and activin receptor 2 (ACTR2), which modulate Smad and p38 MAPK-dependent pathways [24].
Fandel et al. [23] have shown dose-dependent functional
improvements for recovery of erectile function
following bilateral crush injury in the rat, with lower
concentrations of this neurotrophic factor resulting in a
doubling of mean peak intracavernous pressures
(electrostimulation) compared to controls [23]. Follow-up studies
have confirmed the neuromodulatory effects of GDF-5,
as functional recovery is accompanied by nNOS neuronal preservation and decreased levels of apoptosis [25].
GDF-5 is an atypical neuromodulatory agent with some
promise. Although neurobiological properties have not
been fully determined (particularly in the peripheral
nervous system), the bone regenerative properties have been
well characterized in animal models and a human pilot
clinical study is underway for this indication [26].
5 Immunophilin ligands
Immunophilin ligands represent an exciting new class
of agents with well-characterized pre-clinical
neuroprotective and neuroregenerative properties [1]. The
neurotrophic characteristics of immunophilin ligands hold
potential for the treatment of many urological and
non-urological neurotraumatic or neurodegenerative conditions,
including spinal cord injury, peripheral neuropathies, and
ED following radical pelvic surgeries [13, 27].
Immunophilin ligands include cyclosporine and FK 506 (also
known as tacrolimus), agents that bind to immunophilin
receptors and cellular signaling proteins present in
immune and neural tissue [6]. Using models of CN crush
injury in the rat, tacrolimus was found to preserve
function, reduce neural degeneration and stimulate
axonal regrowth [9, 27, 28]. Valentine et
al. [9] recently reported preserved CN architecture with prevention of
CN axonal degeneration following 1-day and 7-day courses of FK 506 treatment, while Sezen
et al. [27] clearly demonstrated functional recovery for FK 506
treated animals versus controls (treatment at time of crush
and on successive days). Concerns remain about the
potential applicability of these therapies in patients treated
for malignancies due to FK 506's immunosuppressant
qualities. However, dose levels of FK 506 used in humans
with rheumatoid arthritis (typically 2_3 mg/day) do not
induce immunosuppression (versus daily 5-mg doses
utilized following transplantation procedures), therefore
supporting further research efforts focused on this
promising pathway [13, 29].
5.1 GPI 1046 and FK 1706 non-immunosuppressant
immunophilin ligands
Non-immunosuppressant forms of immunophilin ligands, such as FK 1706 and GPI 1046, represent a
new class of candidate neurogenerative and neuroprotective compounds which may ultimately may be
preferred to the immunosuppressive immunophilins (FK 506,
cyclosporine A, and rapamycin). Although the
mechanism by which FK 1706 promotes preservation and
functional recovery of neurons is incompletely understood, it
is likely independent of FKBP-12 binding, subsequent
calcineurin inhibition, and the disruption of the cytokine
synthesis cascade [30, 31]. Current evidence suggests
the neuromodulatory actions occur via an anti-apoptotic
effect, protecting neurons by the upregulation of
glutathione (antioxidant) and production of neurotrophic
factors. Immunophilins target only injured nerves and
molecular signaling for FK 1706 and GPI 1046 likely
involves immunophilin type-specific binding proteins
expressed by damaged neurons, as reported for FK 506
[30_32]. For example, the neurotrophic effects specific
to FK 1706 appear to be putatively mediated via FK 506
binding protein (FKBP) subtype-52 and activation of the
Ras/Raf/MAPK signaling pathway, resulting in NGF-mediated neurite outgrowth [33]. Neither calcineurin
inhibition nor binding to FKBP-12 are necessary for the
neurotrophic activity of immunophilin ligands,
suggesting that the neuroregenerative and immunosuppressive
properties can be separated.
In a bilateral CN crush model, FK 1706 has been
shown to enhance the recovery of erectile function in a
concentration dependent manner, with higher dose
treatment group showing a statistically significant elevation
of Intracavernous pressure (ICP) compared to
vehicle-only treated control animals (73.9
vs. 34.4 mean cm H2O) and low/medium
FK 1706 groups (improvement of more than 60%)
[34]. Groups were treated with subcutaneous injection of vehicle (control) alone (1.0 mL/kg), or low
(0.1 mg/kg), medium (0.32 mg/kg) or high dose (1.0
mg/kg) FK 1706 5 days per week for 8 weeks. It is uncertain whether
FK 1706 has more potential in vivo than FK 506, but FK
1706 has proven more effective at provoking NGF-induced neurite outgrowth
in vitro [33]. Oral and intraperitoneal administration of GPI 1046 results in similar
erectile function recovery to that of FK 506 in both
unilateral and bilateral CN-injured animals following
short-term 1- and 7-day administration. Prevention of axonal
degeneration is observed in 83% of unmyelinated axons
[9]. Animals exposed to longer than 5 days duration of
FK 506 treatment have been reported to lose their ability
to gain weight and some expired secondary to chronic,
high-dose FK 506 administration [13, 35]; this morbidity
has not been seen to date with either the Guildford (now
MGI) Pharmaceuticals compound GPI 1046 or Astellas
Pharmaceuticals' FK 1706. An initial clinical trial with
this class of agents using GPI 1485 (phase II multicenter,
randomized double blind placebo-controlled three armed
study) in 197 men undergoing bilateral CN sparing
radical prostatectomy for prostate cancer did not reveal
significant differences between treatment groups [36].
However, further study of the potential of
non-immunosuppressant immunophilin ligands seems warranted as
other neuromodulatory compounds from this group may
demonstrate meaningful efficacy for promoting the
recovery of potency after radical prostatectomy. From a
safety standpoint, GPI 1046 has not shown mitogenic
effects on human prostate cancer cells in
vitro, making it less likely that these molecules will negatively impact
cancer progression or recurrence biology [13, 37].
6 Erythropoetin (EPO)
EPO receptor expression has been localized to
human penile tissues and in the periprostatic neurovascular
bundles responsible for erectile function [38]. Allaf
et al. [39] have also investigated the effects of
recombinant human EPO (rhEPO), a cytokine-hormone, on
erectile function recovery in a rat model of CN injury,
demonstrating statistically significant normalization of
intracavernous pressures compared to controls (treatment
group-rhEPO 5 000 U/kg daily for 14 days versus one
day prior plus one hour prior to injury administration)
for treated cohorts [39]. Electron microscopy confirmed
significant improvement in axonal regeneration for rhEPO
treated groups 14 days after injury. This agent has also
shown CNs efficacy via cytoprotection, neurogenesis,
and decreased subventricular zone morphologic changes
following ischemic brain injury in a rat model of stroke
[40]. As well, EPO increased the percentage of newly
generated neurons. Given these observations, further
molecular and functional studies seem warranted
following CN trauma.
7 Stem cells
Using stem-cell based therapy as a treatment for ED
is an attractive concept and warrants mention; the reader
is also referred to Kendirci's [41] excellent review of
this topic in this issue. In time, stem cells may become
key neuromodulatory agents following CN injury given
that the time of injury is known prior to surgery, penile
anatomy (external) allows for intracavernous introduction,
and retrograde transport of potential therapeutic agents
to the site of injury from the corpora is widely described.
Several animals studies confirm proof-of-concept and
encourage further research into this exciting potential
neuromodulatory approach. Embryonic stem cells (ESC)
that have differentiated along the neuronal cell line have
been injected into the corpus cavernosum, influencing
cavernosal nerve regeneration and functional erectile status
after bilateral crush injury in the rat [40]. In this study,
the maximal increase in intracavernous pressure
following CN electrostimulation at three months was markedly
enhanced for ESC treated groups, and examination of
penile nerves demonstrated a greater degree of nerve
regeneration by immunohistochemical NOS-containing
nerve and neurofilament staining [40]. Kendirci
et al. [41] have demonstrated that injection of nonhematopoetic
bone marrow stem cells that are selected according to
p75 NGF receptor status confer a treatment effect in the
bilateral CN crush rat model as measured by
intracavernous pressure response to electrostimulation. The same
group has also demonstrated similar neuromodulatory
potential using mesechymal stem cells in aged rats [42].
Finally, Lue's group at the University of California San
Francisco have demonstrated that adult adipose
tissue-derived stem cells (ADSCs) increase in
vitro neurite growth from the major pelvic ganglion (from which the
CNs originate) of the rat [43]. The most intriguing
aspect of the latter investigation is that ADSCs were not
induced towards a particular lineage (ie. endothelial or
neural) prior to use.
8 Conclusion
A paradigm shift in the management of prostate
cancer occurred with the introduction of CN-sparing
radical prostatectomy by Walsh and Donker, and the
widespread availability of effective, safe, and well-tolerated
oral therapies for ED. Although cancer-control is the
most important outcome measure for any treatment of
malignancy, a growing emphasis on health-related
quality of life has thrust sexual function into the forefront of
post-operative clinical concerns. Increasing attention has
been given to strategies enhancing CN recovery in the
face of treatments for prostate cancer and possibly other
nontraumatic neurogenic ED disease states such as
diabetes mellitus. Unfortunately, clinical management of
CN injury remains `reactive', as there are currently no
treatments that have been shown to confer therapeutic
benefits if given at or around the time of injury. The
identification of novel molecules that promote CN
regeneration or offer neuroprotection, combined with new
insights for the mechanism(s) of CN recovery, may
translate into novel treatments for neuropathic ED via
neuromodulatory interventions.
Disclosures
Dr Author J. Bella: Eli Lilly Inc., Pfizer Inc.,
American Medical Systems: Consultant/Advisor and Meeting
Participant/Lecturer; Bayer, Boehringer-Ingelheim:
Meeting Participant/Lecturer. Dr Bella is a 2007 Canadian
Urological Association Research Scholar.
Dr Illias Cagiannos and Dr Guiting Lin: None declared.
Dr Tom F. Lue: Consultant/Advisor, Investigator, or
Scientific Study/Trial: Biopharm GmbH,
GSK/Schering-Plough, Eli Lilly Inc., Pfizer Inc., Sanofi Aventis.
References
1 Burnett AL, Lue TF. Neuromodulatory therapy to improve
erectile function recovery outcomes after pelvic surgery. J Urol
2006; 176: 882_7.
2 Mulhall JP, Morgentaler A. Penile rehabilitation should become
the norm for radical prostatectomy patients. J Sex Med 2007; 4:
538_43.
3 Wang R. Penile rehabilitation after radical prostatectomy: where
do we stand and where are we going? J Sex Med 2007; 4: 1085_97.
4 Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use
of an erectogenic pharmacotherapy regimen following radical
prostatectomy improves recovery of spontaneous erectile
function. J Sex Med 2005; 2: 532_40.
5 Mooreland RB. Is there a role of hypoxemia in penile fibrosis: a
viewpoint presented to the Society for the Study of Impotence.
Int J Impot Res 1998; 10: 113_20.
6 Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy:
long-term cancer control and recovery of sexual and urinary
function ("trifecta"). Urology 2005; 66 (5 Suppl): 83_94.
7 Miles C, Candy B, Jones L, Williams R, Tookman A, King M.
Interventions for sexual dysfunction following treatments for
cancer. Cochrane Database Syst Rev 2007: 4; CD005540.
8 Bella AJ, Lin G, Tantiwongse K, Garcia M, Lin CS, Brant W,
et al. Brain-derived neurotrophic factor (BDNF) acts primarily via the
JAK/STAT pathway to promote neurite growth in the major
pelvic ganglion of the rat: Part 1. J Sex Med 2006: 3: 815_20.
9 Valentine H, Chen Y, Guo Y, McCormick J, Wu Y, Sezen SF,
et al. Neuroimmunophilin ligands protect cavernous nerves after
crush injury in the rat: new experimental paradigms. Eur Urol
2007; 51: 1724_31.
10 Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS,
et al. The effect of neural embryonic stem cell therapy in a rat
model of cavernosal nerve injury. BJU Int 2004, 94: 904_9.
11 Palma CA, Keast JR. Structural effects and potential changes in
growth factor signaling in penis-projecting autonomic neurons
after axotomy. BMC Neurosci 2006; 7: 41.
12 Bella AJ, DeYoung L, al-Numi M, Brock GB. Daily
administration of phosphodiesterase type 5 inhibitors for urological and
nonurological indications. Eur Urol 2007; 52: 990_1005.
13 Mulhall J. Neuroimmunophilin ligands protect cavernous nerves
after crush injury in the rat: new experimental paradigms. Eur
Urol 2007; 51: 1488_9.
14 Lin G, Bella AJ, Lue T, Lin CS. Brain-derived neurotrophic
factor (BDNF) acts primarily via the JAK/STAT pathway to
promote neurite growth in the major pelvic ganglion of the rat:
Part 2. J Sex Med 2006; 3: 821_9.
15 Hsieh PS, Bochinski DJ, Lin GT, Nunes L, Lin CS, Lue TF. The
effect of vascular endothelial growth factor and brain-derived
neurotrophic factor on cavernosal nerve regeneration in a
nerve-crush rat model. BJU Int 2003; 92: 470_5.
16 Bella AJ, Lin G, Garcia MM, Tantiwonge T, Lin CS, Brant WO,
et al. Upregulation of penile brain-derived neurotrophic factor
(BDNF) and activation of the JAK/STAT signaling pathway in
the major pelvic ganglion of the rat following cavernous nerve
transection. Eur Urol 2007; 52: 574_81.
17 Hiltunen JO, Laurikainen A, Klinge E, Saarma
M. Neurotrophin-3 is a target derived neurotrophic factor for penile
erection-inducing neurons. Neuroscience 2005; 133: 51_8.
18 Chen KC, Minor TX, Rahman NU, Ho HC, Nunes L, Lue TF.
The additive erectile recovery effect of brain-derived neurotrophic
factor combined with vascular endothelial growth factor in a rat
model or neurogenic impotence. BJU Int 2005; 95: 1077_80.
19 Mitsui T, Fischer I, Shumsky JS, Murray M. Transplants of
fibroblasts expressing BDNF and NT-3 promote recovery of
bladder and hindlimb function following spinal contusion injury
in rats. Exp Neurol 2005; 194: 410_31.
20 Bella AJ, Fandel TM, Tantiwongse K, Brant WO, Klein R, Garcia
CA, et al. Neurturin enhances the recovery of erectile function
following bilateral cavernous nerve crush injury in the rat. J
Brachial Plex Peripher Nerve Inj 2007: 2; 5.
21 Kato R, Wolfe D, Coyle CH, Huang S, Wechuck JB, Goins WF,
et al. Herpes simplex virus vector-mediated delivery of glial cell
line-derived neurotrophic factor rescues erectile dysfunction
following cavernous nerve injury. Gene Ther 2007: 14; 1344_52.
22 Laurikainen A, Hiltunen JO, Thomas-Crusells J, Vanhatalo S,
Arumae U, Airaksinen MS, et al. Neurturin is a neurotrophic
factor for penile parasympathetic neurons in adult rat. J Neurobiol
2000: 43; 198_205.
23 Fandel T, Bella AJ, Tantiwongse K, Garcia M, Nunes L, Thuroff JW,
et al. The effect of intracavernous growth differentiation factor-5 in
a rat model of cavernous nerve injury. BJU Int 2006; 98: 632_36.
24 Sullivan AM, O'Keeffe GW. The role of growth/differentiation
factor 5 (GDF5) in the induction and survival of midbrain
dopaminergic neurons: relevance to Parkinson's disease treatment. J
Anat 2005; 207: 219_26.
25 Fandel TM, Bella AJ, Lin G, Tantiwongse K, Banie L, Thurhoff
JW, et al. Intracavernous growth differentiation factor-5 therapy
enhances the recovery of erectile function in a rat model of
cavernous nerve injury. J Urol 2007; 177: 225 (Abstract 670).
26 Magit DP, Maak T, Trioano N, Raphael B, Hamouria Q,
Polzhofer G, et al. Healos/recombinant human growth and
differentiation factor-5 induces posterolateral lumbar fusion in a
New Zealand white rabbit model. Spine 2006;31:2180_8.
27 Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand
FK 506 is neuroprotective for penile innervation. Nat Med
2001; 710: 1073_4.
28 Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and
sildenafil promote erectile function recovery after cavernous
nerve injury through antioxidative mechanisms. J Sex Med 2007;
4: 908_16.
29 Fleischmann R, Iqbal I, Stern RL. Tacrolimus in rheumatoid
arthritis. Expert Opinion Pharmacother 2006; 7: 91_9.
30 Tanaka K, Asanuma M, Ogawa N. Molecular basis of
anti-apoptotic effect of immunophilin ligands on hydrogen
peroxide-induced apoptosis in human glioma cells. Neurochem Res 2004;
29:1529_36.
31 Hayashi N, Minor TX, Carrion R, Price RD, Nunes L, Lue TF.
Erectile recovery effect of FK1706 following a bilateral
cavernous nerve crush injury in a rat model. J Urol 2006; 176:824_9.
32 Khan Z, Ferrari F, Kasper M, Tonge DA, Steiner JP, Hamilton
GS, et al. The non-immunosuppressive immunophilin ligand
GPI-1046 potently stimulated regenerating axon growth from
adult mouse dorsal root ganglia cultured in Matrigel.
Neuroscience 2002;114:601_9.
33 Price RD, Yamaji T, Yamamoto H, Higashi Y, Hanaoka K,
Yamazaki S, Ishiye M, et al. FK1706, a novel
non-immunosuppressive immunophilin: neurotrophic activity and mechanism of
action. Eur J Pharmacol 2005; 509: 11_9.
34 Bella AJ, Hayashi N, Carrion R, Price R, Lue TF. FK1706
enhances functional recovery following bilateral cavernous nerve
crush injury in a rat model. J Sex Med 2007; 4: 341_47.
35 Burnett AL, Becker RE. Immunophilin ligands promote penile
neurogenesis and erection recovery after cavernous nerve injury.
J Urol 2004; 171: 495_500.
36 Burnett AL, McCullough AR, Smith JA Jr, Montie JE, Walsh PC,
Steiner JP. Neuromodulation to preserve erectile function after
radical prostatectomy: results from the GPI 1485 neuroimmunophilin ligand clinical trial. J Urol 2007; 177:
383_4 (Abstract 1162).
37 Burnett AL, Kramer MF, Dalrymple S, Isaacs JT.
Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in
vitro growth of prostate cancer cells. Urology 2005; 65: 1003_7.
38 Liu T, Allaf ME, Lagoda G, Burnett AL. Erythropoetin receptor
expression in the human urogenital tract: immunolocalization in
the prostate, neurovascular bundle, and penis. BJU Int 2007;
100: 1103_6.
39 Allaf ME, Hoke A, Burnett AL. Erythropoetin promotes the
recovery of erectile function following cavernous nerve injury. J
Urol 2005; 174: 2060_4.
40 Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS,
et al. The effect of neural embryonic stem cell therapy in a rat
model of cavernosal nerve injury. BJU Int 2005; 94: 904_9.
41 Kendirci M, Spees JL, Trost L, Whitney MJ, Prockop DJ,
Hellstrom WJ. Adult bone marrow stem cells isolated by the p75
nerve growth factor receptor into the corpora cavernosa
promoted recovery of erectile function in cavernous nerve injury. J
Sex Med 2006; 3 (Suppl 5): 384 (Abstract OR-008).
42 Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C,
Taylor BK, et al. Mesenchymal stem cells alone or
ex vivo gene modified with endothelial nitric oxide synthase reverse
age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol
2007; 292: H1278_90.
43 Bella AJ, Garcia MM, Lin G, Fandel TM, Brant WO, Lue TF.
Adult adipose tissue derived stem cells enhance neurite outgrowth
from the major pelvic ganglion of the rat. CUAJ 2007; 1: 200
(Abstract 2.01).
|